Rösch AG Medizintechnik
Rösch AG Medizintechnik english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rösch AG announces preliminary figures for the 3rd quarter 2000/2001 Rösch AG Medizintechnik (SIN 529140) announces preliminary figures for the 3rd quarter of the financial year 2000/2001 (reporting period 01.08.2000 – 30.04.2001). Compared to prior year’s period consolidated operating income was increased by about 91% to 6.5 m. Euro. Preliminary actual result for the period determined in accordance with the German Commercial Code (HGB) amounts to about -4.1 m. Euro and thus will turn out about 32% lower than planned. Consolidated operating income of the current financial year is expected to be 7 – 8 m. Euro, and the result for the fourth quarter is estimated to be -1,5 m. Euro. Essential reason for the adjustment in sales and result for the period is the outstanding admittance by the health insurers of the main product, the needle- free injection system INJEX ™ in Germany after the admittance in Norway and France has been carried out (refer to the notifications as of 12.10.00 and 15.05.01). The decision for admittance is in the last authority of “Bundesverband der IKK” at present and is still expected in 2001. The changed forecast for the business years 2001/2002 and 2002/2003 will be presented to the public after admittance by the health insurers, because this will affect the Company’s business planning fundamentally. As announced already contemporaneous with the admittance the Company will start full-coverage advertising activities for the INJEX(tm) system. The Company expects that after the summer break and therefore, in the next business year, the admittance and advertising measurements will show positive effects. Furthermore, the supervisory board of Rösch AG has decided the extension of the management board for the sales area, main responsibility needle-free injection systems / pharmaceutical collaborations, to intensify collaboration negotiations with the pharmaceutical industry. To finance the further growth approximately 15 m. Euro liquid funds are at the disposal of the Company. Rösch AG Medizintechnik – Tel. +49 (30) 66791537 / Email vorstand@roesch-ag.de end of ad hoc announcement (c) DGAP 08.06.2001 ——————————————————————————– WKN: 529 140; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 080752 Jun 01